Protection against Isoproterenol-induced Hypertrophy in H9c2 Cardiomyocytes by Notoginsenoside R1
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The protection of notoginsenoside R1 against isoproterenol-induced hypertrophy in rats H9c2 cardiomyocyte was investigated, and its therapeutic effect on cardiac hypertrophy was also verified. The H9c2 cardiomyocytes was induced by ISO 20 μg/mL to observe the effect of notoginsenoside R1 on cardiac hypertrophy. The viability of cardiomyocytes was detected by MTT assay, and the mRNA levels of ANP, β-MHC, TNF-α, IL-6 and IL-1β were detected by real-time RT-PCR. Western blot was used to detect the protein levels of p65, p-p65, I-κBα; Fluorometric assay kit was used to detect caspase-3 activity. The results showed that, notoginsenoside R1 is effective in inhibiting ISO-induced cardiomyocyte hypertrophy, which manifects increased cardiomyocyte viability, decreased ANP, β-MHC, TNF-α, IL-6 and IL-1β mRNA levels, actived I-κBα protein level, inhibited p65 phosphorylation and decreased Caspase-3 activity. Therefore, notoginsenoside R1 exhibits a protection against ISO-induced H9c2 cardiomyocyte hypertrophy and can effectively inhibit cardiac hypertrophy, and its underlying mechanism may be associated with attenuation of the NF-κB signaling pathway.
